drugset
drugset / Trial / NCT04338659

A Phase 1a Study Evaluating the Safety, Tolerability, and Efficacy of IBI322 in Subjects With Advanced Cancers

NCT04338659 ↗

Phase 1 Completed 22 enrolled Innovent Biologics (Suzhou) Co. Ltd.
NaSequentialOpen-labelTreatment

Summary

This is a phase I study evaluating the safety, tolerability and preliminary efficacy of IBI322 in cancer subjects who failed standard treatment.

Timeline

Start
2021-01-14
Primary completion
2023-02-28
Completion
2023-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject IBI322 Monoclonal antibody — —

Indications

lymphoma